Arcus Biosciences (NYSE:RCUS) Issues Earnings Results

Arcus Biosciences (NYSE:RCUS) issued its quarterly earnings data on Tuesday. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.14, Zacks reports. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%.

Arcus Biosciences Stock Performance

Shares of RCUS stock traded up $0.10 during trading hours on Tuesday, hitting $10.26. 1,159,691 shares of the company were exchanged, compared to its average volume of 910,925. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -3.26 and a beta of 0.84. The firm has a fifty day simple moving average of $13.79 and a 200 day simple moving average of $15.54. Arcus Biosciences has a 52-week low of $10.01 and a 52-week high of $20.31.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RCUS. Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Morgan Stanley lowered their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, HC Wainwright reduced their price objective on shares of Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Insider Activity at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.30% of the stock is owned by company insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.